Anavex Life Sciences Corp. (AVXL)
0.5915
-0.08
(-11.39%)
USD |
NASDAQ |
Nov 20, 16:00
0.611
+0.02
(+3.30%)
After-Hours: 20:00
Anavex Life Sciences Research and Development Expense (TTM) : 11.44M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.44M |
| March 31, 2026 | 26.10M |
| December 31, 2025 | 31.80M |
| September 30, 2025 | 37.59M |
| June 30, 2025 | 41.85M |
| March 31, 2025 | 43.70M |
| December 31, 2024 | 43.54M |
| September 30, 2024 | 41.78M |
| June 30, 2024 | 40.28M |
| March 31, 2024 | 38.76M |
| December 31, 2023 | 40.33M |
| September 30, 2023 | 43.72M |
| June 30, 2023 | 45.04M |
| March 31, 2023 | 44.03M |
| December 31, 2022 | 41.33M |
| September 30, 2022 | 37.92M |
| June 30, 2022 | 35.91M |
| March 31, 2022 | 35.60M |
| December 31, 2021 | 33.71M |
| September 30, 2021 | 32.98M |
| June 30, 2021 | 29.72M |
| March 31, 2021 | 27.48M |
| December 31, 2020 | 26.81M |
| September 30, 2020 | 25.23M |
| June 30, 2020 | 23.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 22.87M |
| December 31, 2019 | 22.90M |
| September 30, 2019 | 22.26M |
| June 30, 2019 | 21.96M |
| March 31, 2019 | 19.20M |
| December 31, 2018 | 16.36M |
| September 30, 2018 | 13.34M |
| June 30, 2018 | 12.77M |
| March 31, 2018 | 12.08M |
| December 31, 2017 | 11.32M |
| September 30, 2017 | 10.67M |
| June 30, 2017 | 11.17M |
| March 31, 2017 | 9.792M |
| December 31, 2016 | 8.626M |
| September 30, 2016 | 7.254M |
| June 30, 2016 | 3.662M |
| March 31, 2016 | 3.544M |
| December 31, 2015 | 2.624M |
| September 30, 2015 | 2.272M |
| June 30, 2015 | 1.869M |
| March 31, 2015 | 1.335M |
| December 31, 2014 | 1.046M |
| September 30, 2014 | 0.7324M |
| June 30, 2014 | 0.4856M |
| March 31, 2014 | 0.2596M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vaxcyte, Inc. | 1.093B |
| Foghorn Therapeutics, Inc. | 76.22M |
| Connect Biopharma Holdings Ltd. | 55.37M |
| Caribou Biosciences, Inc. | 84.72M |
| Oncolytics Biotech, Inc. | 13.18M |